Cancer statistics, 2012, CA: A Cancer Journal for Clinicians, vol.287, issue.suppl 5, pp.10-29, 2012. ,
DOI : 10.3322/caac.20138
Metastatic Hormone Refractory Prostate Cancer, American Journal of Clinical Oncology, vol.37, issue.3, 2012. ,
DOI : 10.1097/COC.0b013e318248dc1e
Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate, AJP: Endocrinology and Metabolism, vol.304, issue.11, pp.1131-1139, 2013. ,
DOI : 10.1152/ajpendo.00602.2012
Angiogenesis in prostate cancer: onset, progression and imaging, BJU International, vol.45, issue.11c, pp.794-808, 2012. ,
DOI : 10.1111/j.1464-410X.2012.11444.x
Targeting angiogenesis for the treatment of prostate cancer, Expert Opinion on Therapeutic Targets, vol.29, issue.21, pp.365-376 ,
DOI : 10.1200/JCO.2007.12.4487
Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design, Anti-Cancer Agents in Medicinal Chemistry, vol.13, issue.5, pp.731-747, 2013. ,
DOI : 10.2174/1871520611313050008
Cellular abnormalities of blood vessels as targets in cancer, Current Opinion in Genetics & Development, vol.15, issue.1, pp.102-111, 2005. ,
DOI : 10.1016/j.gde.2004.12.005
Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies, Cancer Science, vol.156, issue.3, pp.459-466, 2008. ,
DOI : 10.1101/gad.436307
URL : http://doi.org/10.1111/j.1349-7006.2007.00704.x
Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities, Cancer Research, vol.64, issue.22, pp.8249-8255, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-1567
URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.585.1563
Altered angiogenesis and survival in human tumor-derived endothelial cells, The FASEB Journal, vol.17, pp.1159-1161, 2003. ,
DOI : 10.1096/fj.02-0557fje
Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature, Blood, vol.108, issue.7, pp.2339-2348, 2006. ,
DOI : 10.1182/blood-2006-02-004291
Tumor endothelial cells have features of adult stem cells, Cell Cycle, vol.8, issue.2, pp.236-238, 2009. ,
DOI : 10.4161/cc.8.2.7413
Tumor exploits alternative strategies to achieve vascularization, The FASEB Journal, vol.25, issue.9, pp.2874-2882, 2001. ,
DOI : 10.1096/fj.10-180323
Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures, Experimental Cell Research, vol.312, issue.6, pp.913-924, 2006. ,
DOI : 10.1016/j.yexcr.2005.12.004
Expression of Pax2 in Human Renal Tumor-Derived Endothelial Cells Sustains Apoptosis Resistance and Angiogenesis, The American Journal of Pathology, vol.168, issue.2, pp.706-713, 2006. ,
DOI : 10.2353/ajpath.2006.050776
Human Hepatocellular Carcinoma Tumor-derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared with Normal Endothelial Cells, Clinical Cancer Research, vol.15, issue.15, pp.4838-4846, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2780
Calcification of Multipotent Prostate Tumor Endothelium, Cancer Cell, vol.14, issue.3, pp.201-211, 2008. ,
DOI : 10.1016/j.ccr.2008.06.017
Isolation and characterization of human breast tumor-derived endothelial cells, Oncology Reports, vol.15, pp.381-386, 2006. ,
DOI : 10.3892/or.15.2.381
Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA, Blood, vol.110, issue.7, pp.2440-2448, 2007. ,
DOI : 10.1182/blood-2007-03-078709
Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function, Journal of Clinical Investigation, vol.117, issue.6, pp.1647-1657, 2007. ,
DOI : 10.1172/JCI30168DS1
URL : https://hal.archives-ouvertes.fr/inserm-00137718
Canonical Transient Receptor Potential 1 Plays a Role in Basic Fibroblast Growth Factor (bFGF)/FGF Receptor-1-Induced Ca2+ Entry and Embryonic Rat Neural Stem Cell Proliferation, Journal of Neuroscience, vol.25, issue.10, pp.2687-2701, 2005. ,
DOI : 10.1523/JNEUROSCI.0951-04.2005
Sorafenib in progressive castrateresistant prostate cancer. can we talk about a new therapeutic option, Arch Med Sci, vol.8, pp.528-532, 2012. ,
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy, Annals of Oncology, vol.21, issue.2, pp.319-324, 2010. ,
DOI : 10.1093/annonc/mdp323
URL : http://annonc.oxfordjournals.org/cgi/content/short/21/2/319
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients, Expert Opinion on Pharmacotherapy, vol.5, issue.20, pp.2433-2439, 2011. ,
DOI : 10.1016/j.ejca.2009.02.011
VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis, The EMBO Journal, vol.277, issue.13, pp.2342-2353, 2005. ,
DOI : 10.1038/sj.emboj.7600709
Androgen Receptor Is Causally Involved in the Homeostasis of the Human Prostate Endothelial Cell, Endocrinology, vol.149, issue.6, pp.2959-2969, 2008. ,
DOI : 10.1210/en.2007-1078
exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, vol.64, pp.43-90067099, 2004. ,
IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer, Clinical Cancer Research, vol.17, issue.8, pp.2538-2548, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-3314
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells, Cell Death and Disease, vol.22, issue.1, p.262, 2012. ,
DOI : 10.1038/cddis.2012.1
Tumor-associated endothelial cells display GSTP1 and RAR beta2 promoter methylation in human prostate cancer, Journal of Translational Medicine, vol.4, issue.1, p.13, 2006. ,
DOI : 10.1186/1479-5876-4-13
Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue, Oncotarget, vol.4, issue.9, pp.1472-1483, 2013. ,
DOI : 10.18632/oncotarget.1269
Anti-angiogenic therapies in prostate cancer, Expert Opinion on Biological Therapy, vol.361836, issue.1, pp.1-5, 2013. ,
DOI : 10.1016/j.leukres.2010.07.038
Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone versus prednisone alone in men with progressive metastatic castration-resistant prostate cancer, J ClinOncol, vol.2014, issue.322, pp.76-82 ,
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV, British Journal of Cancer, vol.14, issue.11, pp.1480-1527, 2007. ,
DOI : 10.1158/0008-5472.CAN-04-1443
Page 12 of 13 http://www.biomedcentral.com/1471-2407/14/939 A Phase II clinical trial of sorafenib in androgen-independent prostate cancer, BMC Cancer Clin Cancer Res, vol.14, issue.14, pp.939209-214, 2008. ,
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer, BJU International, vol.16, issue.12, pp.1636-1640, 2009. ,
DOI : 10.1111/j.1464-410X.2008.08327.x
Phase II study of sunitinib in men withadvanced prostate cancer, pp.913-920, 2009. ,
Angiogenic Inhibition of Sunitinib Malate, Current Eye Research, vol.70, issue.7, pp.567-574, 2012. ,
DOI : 10.1167/iovs.05-0772
Multiple receptor tyrosine kinases regulate HIF-1?? and HIF-2?? in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors, Oncogene, vol.60, issue.20, pp.2938-2949, 2010. ,
DOI : 10.1007/s11060-005-3279-0
Cytotoxic Properties of Sunitinib and Sorafenib on Human Corneal Epithelial Cells, Current Eye Research, vol.45, issue.2, pp.149-154, 2013. ,
DOI : 10.1097/ICO.0b013e31823f8b9c
The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway, Journal of Molecular Medicine, vol.63, issue.10, pp.852-863, 2006. ,
DOI : 10.1007/s00109-006-0075-z
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer, Investigational New Drugs, vol.375, issue.1, pp.1652-1659, 2012. ,
DOI : 10.1007/s10637-011-9722-5